TXG - 10x Genomics Inc Broker Consensus Forecast

Corporate company logo of 10x Genomics Inc (TXG)

Compliance with ESG environmental standards is forcing 10x Genomics, Inc. (TXG) to reduce packaging volume and implement recyclable plastics. A market price reaching 68.22, as confirmed by this chart, accompanies the single-cell analysis leader, which is protected by a powerful patent portfolio. The business generates revenue through the sale of high-precision equipment and consumables. However, the pace of customer base expansion has currently slowed, temporarily reducing operational efficiency due to marketing expenses.

10x Genomics Inc (TXG) Analyst Consensus Forecast: for the period 07/04/2022 - 11/11/2026
Manufactured products of 10x Genomics Corp

This indicator determines the fair value of an asset by aggregating expert estimates. The investment community's average benchmark visualizes the dynamics of expected capital relative to the market price. The metric compares actual revenue with collective Wall Street forecasts to identify overbought or undervalued conditions. For 10x Genomics, Inc. (TXG), the upward trend of the line confirms the value of recurring revenue from consumables. Stable cash flow from unique technologies makes this forecast a reliable basis for valuation.

Who 10x Genomics, Inc. competes with

Analyst Forecast Prices TEM|Qiagen - Consensus Target|IONS: Broker Consensus Forecast|Repligen Corp. - Analyst Consensus Forecast|Analyst Target Range Avidity Corp (RNA)|CRSP: Analyst Consensus Forecast|Broker Consensus Forecast WGS|Price Target Chart Ultragenyx|Broker Consensus Forecast BEAM (Beam Therapeutics Inc)|Analyst Consensus Forecast SRPT|Analyst Consensus Forecast Twist Bioscience Corp (TWST)|Analyst Consensus Forecast NTLA (Intellia Therapeutics)|Analyst Forecast Prices STOK (stoketherapeutics.com)|BLFS: Consensus Target|WVE (Wave Life Sciences Ltd) - Broker Consensus Forecast|MAZE (Maze Tx) - Consensus Target|Sionna Corp - Fair Value Consensus|PRME (Prime Medicine, Inc.) - Analyst Consensus Forecast|TSHA - Analyst Target Range|Analyst Consensus Forecast QURE|MGTX - Average Forecast Price|Price Target Chart Regenxbio RGNX|SLDB: Broker Consensus Forecast|OCGN - Price Target Chart|Average Forecast Price pacb.com|Benitec Biopharma (BNTC) - Price Target Chart|Consensus Target Design Therapeutics Inc|RCKT (Rocket Pharmaceuticals Inc) - Analyst Consensus Forecast|4D Molecular Corp (FDMT) - Analyst Median Target|Analyst Consensus Forecast LXEO|Consensus Target korrobio.com KRRO|Price Target Chart Editas Medicine EDIT|Analyst Median Target Silence Therapeutics PLC (SLN)|PRQR: Consensus Target|Fair Value Consensus CDXS (Codexis, Inc.)|SGMO: Analyst Consensus Forecast|NAUT - Analyst Median Target|Price Target Chart Metagenomi|Broker Consensus Forecast DTIL (Precision BioSciences Inc.)|Analyst Consensus Forecast GBIO|Consensus Target Boundless Bio Inc BOLD|Exicure - Consensus Target|Analyst Median Target Imunon Inc (IMNN)|PHIO: Consensus Target|Mustang Bio, Inc. - Analyst Forecast Prices|RNAZ (transcodetherapeutics.com) - Consensus Target|Broker Consensus Forecast BNGO|APDN (Applied DNA Sciences) - Analyst Consensus Forecast|BLUE - Analyst Target Range|Analyst Consensus Forecast IPA|Omega Therapeutics Inc - Broker Consensus Forecast|Price Target Chart Singular Genomics Systems Inc OMIC|RGLS: Broker Consensus Forecast|Syros Pharmaceuticals - Analyst Consensus Forecast|TBIO - Analyst Consensus Forecast|TCON: Analyst Consensus Forecast|UBX: Analyst Forecast Prices